JP Morgan Chase
STML

JP Morgan Chase’s Stemline Therapeutics, Inc. STML Stock Holding History

JP Morgan Chase’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-12,000
Closed -$114K – 6178
2018
Q4 		$114K Buy
+12,000
New +$156K ﹤0.01% 4802

JP Morgan Chase's STML Position: Q2 2020 in Review

JP Morgan Chase sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 15,085 shares — an estimated $73K sold.

JP Morgan Chase first reported a position in STML in Q2 2013 and held it in 16 quarters. The position peaked at $6.47M in Q3 2013. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

  • JP Morgan Chase reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • JP Morgan Chase sold 15,085 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $73K.
  • JP Morgan Chase first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 16 quarters.
  • JP Morgan Chase's Stemline Therapeutics, Inc. position peaked at $6.47M in Q3 2013.
  • 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on JP Morgan Chase's 13F filing for Q2 2020, filed 11 Aug 2020.